Priority action during neuromuscular blockade
A patient receiving a continuous neuromuscular blocker (NMB) infusion is chemically paralyzed but remains fully conscious unless adequate sedation and analgesia are provided. The most dangerous situation is one in which sedation is interrupted while paralysis continues, because the patient may be awake, aware of the ventilator, and unable to move or communicate. In this scenario, the sedative infusion was paused at
08:30 for a daily awakening trial while cisatracurium is still running. That combination creates a risk of awake paralysis and must be corrected before any other assessment finding is addressed.
Neuromuscular blockers paralyze but provide no sedation or analgesia, so a client receiving one must stay deeply sedated. Daily awakening trials, which involve interrupting or minimizing sedation to assess neurologic status and readiness for weaning, are withheld while an NMB is infusing. The rationale is not simply a protocol detail; it reflects the pharmacology of NMBs. Cisatracurium binds nicotinic acetylcholine receptors at the neuromuscular junction, preventing muscle contraction, but it does not cross the blood–brain barrier in clinically meaningful amounts and has no effect on consciousness. If the sedative is stopped, the patient may become fully alert while unable to move, blink, or breathe spontaneously. This is a medical emergency because it causes severe psychological distress, sympathetic surge, and loss of ventilator synchrony.
Watch out! A train-of-four result of
2 of 4 twitches is within the stated target of
1–2 of 4, so it does not require immediate action. The oxygen saturation of
90% is also within the protocol target of
88–95%. Incomplete eyelid closure with mildly dry corneas is a real concern during NMB infusion because paralysis prevents blinking and full lid closure, but it is a lower-acuity problem than awake paralysis. Eye lubrication and moisture-chamber protection should be initiated, but only after the sedation interruption is corrected.
The priority action is to resume the sedative infusion immediately and notify the team that a daily awakening trial was attempted during NMB therapy.
Daily awakening trials are withheld while a neuromuscular blocker is running. Once the NMB is discontinued and neuromuscular function has recovered sufficiently, sedation interruption can be reconsidered. The clinical concern surrounding NMB use in the ICU has historically included prolonged weakness and other complications, but current evidence emphasizes that protocolized care, appropriate monitoring, and attention to sedation adequacy can reduce these risks. The key safety principle remains unchanged: paralysis without sedation is never acceptable.
| Finding | Target or expected finding | Priority |
|---|
| Train-of-four 2/4 | Within target (1–2/4) | Monitor only |
| SpO2 90% | Within protocol range (88–95%) | Monitor only |
| Incomplete eyelid closure, dry corneas | Expected with NMB; requires eye care | Address after urgent issue |
| Sedative paused at 08:30 during NMB infusion | Contraindicated; risk of awake paralysis | Act first |
Key point! When a patient is receiving a continuous NMB, the nurse must verify that sedation and analgesia are running before performing any other assessment or intervention. A sedation hold during paralysis is the highest-priority safety violation in this scenario.